Citigroup Inc. Sells 2,390 Shares of Medpace Holdings, Inc. $MEDP

Citigroup Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,646 shares of the company’s stock after selling 2,390 shares during the period. Citigroup Inc.’s holdings in Medpace were worth $49,692,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Fifth Third Wealth Advisors LLC grew its position in shares of Medpace by 2.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock worth $379,000 after buying an additional 19 shares during the last quarter. HighPoint Advisor Group LLC raised its holdings in shares of Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after acquiring an additional 22 shares in the last quarter. Portside Wealth Group LLC lifted its stake in Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after acquiring an additional 27 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its holdings in Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after acquiring an additional 27 shares in the last quarter. Finally, M&T Bank Corp increased its position in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 80,328 shares of company stock valued at $48,219,399 over the last 90 days. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Truist Financial decreased their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Leerink Partners lowered their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Barclays reduced their target price on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a report on Wednesday, February 11th. Finally, Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $483.45.

Medpace Stock Performance

Shares of MEDP opened at $444.96 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The firm’s 50-day simple moving average is $553.73 and its two-hundred day simple moving average is $539.55. The stock has a market cap of $12.63 billion, a PE ratio of 29.08, a price-to-earnings-growth ratio of 2.17 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.